| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/29/2001 | WO2001021786A1 Method of screening disease depressant gene |
| 03/29/2001 | WO2001021775A1 Gene encoding novel human secretory phospholipase a¿2? |
| 03/29/2001 | WO2001021773A2 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021771A2 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | WO2001021765A2 Method for the selective protection of proliferating normal cells and the selective eradication of tumor cells having an inactive p53 pathway |
| 03/29/2001 | WO2001021764A1 A pcra helicase of staphylococcus aureus |
| 03/29/2001 | WO2001021761A2 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 03/29/2001 | WO2001021663A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021661A1 BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX |
| 03/29/2001 | WO2001021660A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 03/29/2001 | WO2001021659A1 Novel protein component and encoding nucleic acid |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021656A2 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 03/29/2001 | WO2001021653A2 Ovarian tumor antigen and methods of use therefor |
| 03/29/2001 | WO2001021651A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021648A1 Uses of kappa-conotoxin pviia |
| 03/29/2001 | WO2001021647A2 Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| 03/29/2001 | WO2001021645A2 Target for antiviral therapy |
| 03/29/2001 | WO2001021643A2 Parathyroid hormone analogues for the treatment of osteoporosis |
| 03/29/2001 | WO2001021641A1 Compositions and methods for the diagnosis and treatment of immune disorders |
| 03/29/2001 | WO2001021634A1 Benzimidazole derivatives and combinatorial libraries thereof |
| 03/29/2001 | WO2001021631A2 Secreted proteins and uses thereof |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021574A1 Systems and methods for opening obstructed biological conduits |
| 03/29/2001 | WO2001021259A2 Use and compositions for treating platelet-related disorders using anagrelide |
| 03/29/2001 | WO2001021215A1 Cell based assay |
| 03/29/2001 | WO2001021214A1 Gene therapy for cerebrovascular disorders |
| 03/29/2001 | WO2001021213A2 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021202A2 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells |
| 03/29/2001 | WO2001021198A1 Method for reducing the risk of cancer |
| 03/29/2001 | WO2001021197A1 Synthesis of insulin derivatives |
| 03/29/2001 | WO2001021196A1 Method and compositions for inhibiting adhesion formation |
| 03/29/2001 | WO2001021194A2 Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| 03/29/2001 | WO2001021193A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | WO2001021192A2 Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| 03/29/2001 | WO2001021191A2 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 03/29/2001 | WO2001021190A1 Treatment for narcolepsy |
| 03/29/2001 | WO2001021189A1 Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| 03/29/2001 | WO2001021188A1 Utilization of fprl1 as a functional receptor by serum amyloid a (saa) |
| 03/29/2001 | WO2001021184A1 Cell-based gene therapy for the pulmonary system |
| 03/29/2001 | WO2001021163A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/29/2001 | WO2001021159A2 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 03/29/2001 | WO2001021154A2 Surface modified particulate compositions of biologically active substances |
| 03/29/2001 | WO2001007067A3 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 03/29/2001 | WO2001005419A3 Agent for treating cardiac diseases |
| 03/29/2001 | WO2001002557A8 Neurotrophic factor receptor |
| 03/29/2001 | WO2000077026A8 49 human secreted proteins |
| 03/29/2001 | WO2000068250A8 7tm receptor rat apj |
| 03/29/2001 | WO2000066176A3 Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors |
| 03/29/2001 | WO2000064939A3 Peptides derived from vasostatin i and the use thereof as anti-fungal agents |
| 03/29/2001 | WO2000061742A3 Treatment of cardiac power failure using s100 proteins |
| 03/29/2001 | WO2000061182A3 Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist |
| 03/29/2001 | WO2000061067A3 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein |
| 03/29/2001 | WO2000056871A3 CELLS COEXPRESSING AN AMYLOID PRECURSOR PROTEIN AND AN α-SECRETASE AND THEIR USES IN TEST METHODS AND DIAGNOSTICS |
| 03/29/2001 | WO2000052148A3 Substances for controlling fertility |
| 03/29/2001 | WO2000037487A8 αvβ6 INTEGRIN INHIBITORS |
| 03/29/2001 | WO2000032775A9 Pth1r and pth3r receptors |
| 03/29/2001 | WO2000031290A9 Methods and compositions for pain management |
| 03/29/2001 | WO2000020607A9 Chimaeric proteins between members of tgf-beta superfamily |
| 03/29/2001 | WO2000012741A9 Inducible expression system |
| 03/29/2001 | WO1999062535A3 Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases |
| 03/29/2001 | WO1999050282A3 Peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases |
| 03/29/2001 | US20010000075 Neurotactin and uses therefor |
| 03/29/2001 | DE19945211A1 New autoantibody-binding peptides with an amino acid sequence corresponding a beta1-adrenergic receptor group useful for treating dilatative cardiomyopathy |
| 03/29/2001 | DE19945210A1 New autoantibody-binding peptides with an amino acid sequence corresponding a beta1-adrenergic receptor group, useful for treating dilatative cardiomyopathy |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2793128A1 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 03/29/2001 | CA2388417A1 Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| 03/29/2001 | CA2387695A1 A novel member of the heparanase protein family |
| 03/29/2001 | CA2387693A1 Method for monitoring treatment with a parathyroid hormone |
| 03/29/2001 | CA2386767A1 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385813A1 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385783A1 A pcam-1 marker protein, nucleic acid sequences encoding pcam-1 and immunoassays for detection of pcam-1 |
| 03/29/2001 | CA2385778A1 Modulation of ige receptor cell surface expression |
| 03/29/2001 | CA2385697A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385496A1 Molecules for diagnostics and therapeutics |
| 03/29/2001 | CA2385488A1 Systems and methods for opening obstructed biological conduits |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2385425A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385424A1 Method for the selective protection of proliferating normal cells and the selective eradication of tumor cells having an inactive p53 pathway |
| 03/29/2001 | CA2385406A1 Gene encoding novel human secretory phospholipase a2 |
| 03/29/2001 | CA2385264A1 Method for determining the fertility of mammals, especially of humans |
| 03/29/2001 | CA2385257A1 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | CA2385228A1 Ribozymes used for restenosis prevention |
| 03/29/2001 | CA2385047A1 Uses of kappa-conotoxin pviia |
| 03/29/2001 | CA2384816A1 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 03/29/2001 | CA2384812A1 Method and compositions for inhibiting adhesion formation |
| 03/29/2001 | CA2384341A1 Parathyroid hormone analogues for the treatment of osteoporosis |
| 03/29/2001 | CA2383629A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | CA2383615A1 Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383591A1 Cell based assay |
| 03/29/2001 | CA2383574A1 Method for reducing the risk of cancer |
| 03/29/2001 | CA2383510A1 Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2383462A1 Therapeutic methods and compounds |
| 03/29/2001 | CA2383253A1 Conditional immortalisation of cells |